Key result
A hybrid compound demonstrating dual inhibition of CB1R and iNOS was highlighted as a potential new therapeutic strategy to simultaneously reduce LDL and VLDL levels in a mouse model.
Why the study?
Does a hybrid compound with dual inhibition of CB1R and iNOS reduce LDL and VLDL levels in a mouse model of diabetic dyslipidemia?
Does a hybrid compound with dual inhibition of CB1R and iNOS reduce LDL and VLDL levels in a mouse model of diabetic dyslipidemia?
No takes yet. Share an insight, caveat, or question.
A hybrid compound with dual inhibition of CB1R and iNOS represents a potential new therapeutic strategy to simultaneously reduce LDL and VLDL levels in diabetic dyslipidemia.
Kothari et al. (2020) conducted an editorial in Diabetic dyslipidemia. Hybrid compound (dual inhibition of CB1R and iNOS) was evaluated on LDL and VLDL levels. A hybrid compound demonstrating dual inhibition of CB1R and iNOS was highlighted as a potential new therapeutic strategy to simultaneously reduce LDL and VLDL levels in a mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: